About: Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium
Creator	Fearon, Margaret Golder, Mia Schubert, Peter Solh, Ziad Sheffield, William Shih, Andrew Walsh, Geraldine
source	Elsevier; Medline; PMC
abstract	Abstract Testing donations for pathogens and deferring selected blood donors have reduced the risk of transmission of known pathogens by transfusion to extremely low levels in most developed countries. Protecting the blood supply from emerging infectious threats remains a serious concern in the transfusion medicine community. Transfusion services can employ indirect measures such as surveillance, hemovigilance, and donor questioning (defense), protein-, or nucleic acid based direct testing (detection), or pathogen inactivation of blood products (destruction) as strategies to mitigate the risk of transmission-transmitted infection. In the North American context, emerging threats currently include dengue, chikungunya, and hepatitis E viruses, and Babesia protozoan parasites. The 2003 SARS and 2014 Ebola outbreaks illustrate the potential of epidemics unlikely to be transmitted by blood transfusion but disruptive to blood systems. Donor-free blood products such as ex vivo generated red blood cells offer a theoretical way to avoid transmission-transmitted infection risk, although biological, engineering, and manufacturing challenges must be overcome before this approach becomes practical. Similarly, next generation sequencing of all nucleic acid in a blood sample is currently possible but impractical for generalized screening. Pathogen inactivation systems are in use in different jurisdictions around the world, and are starting to gain regulatory approval in North America. Cost concerns make it likely that pathogen inactivation will be contemplated by blood operators through the lens of health economics and risk-based decision making, rather than in zero-risk paradigms previously embraced for transfusable products. Defense of the blood supply from infectious disease risk will continue to require innovative combinations of surveillance, detection, and pathogen avoidance or inactivation.
has issue date	2016-04-30(xsd:dateTime)
bibo:doi	10.1016/j.tmrv.2016.02.003
bibo:pmid	26962008
has license	els-covid
sha1sum (hex)	d40f2e2126acaf365d3b5dbe93e3a2b7982907c3
schema:url	https://doi.org/10.1016/j.tmrv.2016.02.003
resource representing a document's title	Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium
has PubMed Central identifier	PMC7126603
has PubMed identifier	26962008
schema:publication	Transfusion Medicine Reviews
resource representing a document's body	covid:d40f2e2126acaf365d3b5dbe93e3a2b7982907c3#body_text
is schema:about of	named entity 'NGS' named entity 'emergency plan' named entity 'risk management' named entity 'unit testing' named entity 'cytokine' named entity 'CHIKV' named entity 'human papilloma virus' named entity 'global issue' named entity 'endothelial cell functions' named entity 'arboviruses' named entity 'RBCs' named entity 'blood supply' named entity 'poverty-stricken' named entity 'Plasmodium species' named entity 'human T-lymphotropic virus' named entity 'sequencing by synthesis' named entity 'Chagas' named entity 'human species' named entity 'muscle' named entity 'viruses' named entity 'NGS' named entity 'germ layers' named entity 'massively parallel' named entity 'platelet' named entity 'AABB' named entity 'Aedes' named entity 'WNV' named entity 'cost-utility analysis' named entity 'Sierra Leone' named entity 'HSPCs' named entity 'viruses' named entity 'University of Toronto' named entity 'viruses' named entity 'platelets' named entity 'T cruzi' named entity 'Alzheimer's disease' named entity 'platelet' named entity 'WNV' named entity 'Pathogen' named entity 'Microbial' named entity 'pathogen' named entity 'cost-effective' named entity 'United States' named entity 'North America' named entity 'rhinovirus' named entity 'deforestation' named entity 'Ebola outbreak in West Africa' named entity 'NGS' named entity 'Chagas' named entity 'University of Edinburgh' named entity 'National Microbiology Laboratory' named entity 'emerging infections' named entity '2.2' named entity 'virus' named entity 'CMV' named entity 'culicine mosquitoes' named entity 'pathogen' named entity 'Biogen' named entity 'HBsAg' named entity 'epidemic' named entity 'Mount Sinai Hospital' named entity 'NGS' named entity 'Canadian' named entity 'blood-borne' named entity 'MinION' named entity 'cell growth rate' named entity 'pathogen' named entity 'endemic' named entity 'Chagas disease' named entity 'platelet' named entity 'Sub-Saharan Africa' named entity 'RBC' named entity 'Urbanization' named entity 'transfusion medicine' named entity 'NGS methodology'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software